Alzheimer’s & Dementia: Translational Research & Clinical Interventions (Jan 2021)

Herpesvirus infections, antiviral treatment, and the risk of dementia—a registry‐based cohort study in Sweden

  • Karin Lopatko Lindman,
  • Eva‐Stina Hemmingsson,
  • Bodil Weidung,
  • Jon Brännström,
  • Maria Josefsson,
  • Jan Olsson,
  • Fredrik Elgh,
  • Peter Nordström,
  • Hugo Lövheim

DOI
https://doi.org/10.1002/trc2.12119
Journal volume & issue
Vol. 7, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction Herpesviruses, including Herpes simplex virus type 1 (HSV1) and varicella zoster‐virus (VZV), have been implicated in Alzheimer's disease (AD) development. Likewise, antiviral treatment has been suggested to protect against dementia development in herpes‐infected individuals. Methods The study enrolled 265,172 subjects aged ≥ 50 years, with diagnoses of VZV or HSV, or prescribed antiviral drugs between 31 December 2005 and 31 December 2017. Controls were matched in a 1:1 ratio by sex and birth year. Results Antiviral treatment was associated with decreased risk of dementia (adjusted hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.86 to 0.92), while herpes infection without antiviral drugs increased the risk of dementia (adjusted HR 1.50, 95% CI 1.29 to 1.74). Discussion Antiviral treatment was associated with a reduced long‐term risk of dementia among individuals with overt signs of herpes infection. This is consistent with earlier findings indicating that herpesviruses are involved in the pathogenesis of AD.

Keywords